

Dasiglucagon: Adis Evaluation

Clinical Considerations

- First ready-to-use aqueous formulation; no need to reconstitute
- Available in convenient auto-injector and prefilled syringe forms; can be carried at room temperature
- Indicated in the USA for the rescue treatment of severe hypoglycaemia in patients aged ≥ 6 years with diabetes
- A single dose reverses insulin-induced hypoglycemia within a median 10 min, without need for additional intervention
- Generally well tolerated, with nausea and vomiting being the most frequent adverse reactions

Plain Language Summary

Background and rationale

- Glucagon emergency kits are a standard treatment option for hypoglycemia, a potential serious complication of diabetes treatment
- The kits require mixing of glucagon powder in sterile water before administration; this step may cause errors and delay in an emergency situation
- Subcutaneous dasiglucagon (Zegalogue®) is a ready-to-use glucagon, approved in the USA for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes

Clinical findings

- A single dose of dasiglucagon reverses hypoglycemia typically within 10 min, without need for additional intervention, and it has a good tolerability profile
- The drug is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature and administered by patients and caregivers

Conclusion

Dasiglucagon is a convenient and valuable addition to ready-to-use glucagon formulations for the treatment of severe hypoglycemia

This plain language summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.